As was reported by dales, the fdas ""denial"" and request for dialogue has NOTHING to do with the veracity of the data, but rather is merely a procedural obstacle.
---Yes, This has nothing to do with the data, and the fact that this trial was not shut down has to prove that efficacy is there, and they need to look at a larger sample size. This appears to not be a cause of worry for us longs.
The question I still am a little fuzzy on, albeit probably thinking more clearly than Tua Tagovailoa, is MF, our head coach, advised by the three doctors I mentioned in a prior post, already met with the FDA and decided that the pcr test would be a good endpoint. What changed? Were they looking for a higher percentage than we got on the test, but still see another path to EUA?
GLTA.
News 
Market Data 
Discover 
